FDA Approves First mRNA Flu Vaccine
The FDA approved Moderna's mFlusiva, the first seasonal influenza vaccine using mRNA technology to enter the US market.
The FDA approved Moderna's mFlusiva, the first seasonal influenza vaccine using mRNA technology to enter the US market.
Results from the HOPE-3 trial found that an investigational cell therapy called deramiocel preserved heart and muscle function in boys and young men with Duchenne muscular dystrophy (DMD).
For patients in the pediatric ICU, pulse oximetry and waveform capnography are valuable tools to monitor the effectiveness of respiratory support and to inform treatment decisions.
The collaboration will combine flow cytometry and proteomic analysis to help ID specific inflammatory pathways for chronic lung diseases.
A proof-of-concept study showed an experimental monoclonal antibody targeting ARDS inflammation increased ventilator-free days and reduced organ failure.
A TB blood test identifies a bacterial marker to distinguish between active and latent tuberculosis infections.
New research suggests acoustic speech features can identify respiratory exacerbations from the first day of onset.